Emeryville, CA – According to filings with the U.S. Securities and Exchange Commission, Nutcracker Therapeutics is raising $199,999,994.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Igor Khandros played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nutcracker Therapeutics
Nutcracker Therapeutics is an early stage biotech disrupter founded to develop mRNA-based therapeutic drug products which will be manufactured on our novel ACORN (Automation COntroled RNA) microfluidic based manufacturing system. ACORN is a fully automated, software-controlled microfluidics platform. Our advanced technology-driven approach to therapeutics manufacturing addresses significant challenges associated with production and scale-up of therapeutic products. Automation and microfluidics deliver significantly reduced production cycle times, increased process control, efficiency and reproducibility while greatly reducing manual manipulations, risks of contamination and costly facilities. Through the introduction of breakthrough therapeutic micro factories, Nutcracker is poised to deliver on our mission to significantly improve patients lives.

To learn more about Nutcracker Therapeutics, visit http://www.nutcrackerx.com/

Contact:
Igor Khandros, Chief Executive Officer
510-473-8478

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved